In another Phase I trial, HLA-A24-specific survivin-2B vaccine was administered to 15 patients with advanced or recurrent CRC expressing survivin, with one patient showing an increase in survivin-specific CTLs and six showing decreased CEA levels [65]. This evidence concerns the gene CEACAM5 and colorectal carcinoma.